SCHEMBL353230

SCHEMBL353230

CCNC(=O)c1cccnc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.72
GAA P10253 1/20 0.70
MEN1 O00255 3/20 0.63
KMT2A Q03164 3/20 0.63
HDAC1 Q13547 2/20 0.62
HDAC6 Q9UBN7 1/20 0.62
CYP1A2 P05177 1/20 0.61
CYP3A4 P08684 1/20 0.61
RAB9A P51151 4/20 0.60
NPC1 O15118 3/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
HDAC3 O15379 1/20 0.59
HDAC2 Q92769 1/20 0.59
TSHR P16473 1/20 0.59
EPHX2 P34913 2/20 0.57
LMNA P02545 2/20 0.57
ALDH1A1 P00352 2/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
KDM4E B2RXH2 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31314589 1.00 THRB (0.72) THRBGAAMEN1KMT2AHDAC1
SCHEMBL31175967 0.98 THRB (0.70) THRBGAAMEN1KMT2AHDAC1
Fluoride SCHEMBL11495080 0.98 THRB (0.70) THRBGAAMEN1KMT2AHDAC1
Acetic Acid SCHEMBL28287265 0.95 THRB (0.66) THRBGAAMEN1KMT2AHDAC1
Nitric Acid SCHEMBL28384651 0.91 KMT2A (0.61) THRBGAAMEN1KMT2AHDAC1
SCHEMBL13614959 0.89 THRB (0.67) THRBGAAMEN1KMT2AHDAC1
SCHEMBL2497123 0.86 THRB (0.68) THRBGAAMEN1KMT2AHDAC1
SCHEMBL25328235 0.85 THRB (0.77) THRBGAAMEN1KMT2AHDAC1
SCHEMBL14415899 0.85 THRB (0.77) THRBGAAMEN1KMT2AHDAC1
SCHEMBL29572289 0.85 THRB (0.66) THRBGAAMEN1KMT2AHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 748 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122094660-A Composition in the form of an oil-in-water emulsion 2026-05-26 CN claimed
EP-4687829-A1 COMPOSITION FOR CARING FOR KERATIN MATERIALS L'OREAL (FR) 2026-02-11 EP claimed
US-20250381116-A1 SOLUBILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME OREAL (FR) 2025-12-18 US claimed
US-20250161201-A1 COSMETIC COMPOSITION THE BOOTS COMPANY PLC (GB) 2025-05-22 US claimed
WO-2025091220-A2 COMPOSITION IN THE FORM OF OIL-IN-WATER EMULSION L'OREAL (FR) 2025-05-08 WO claimed
WO-2025091239-A1 COMPOSITION IN THE FORM OF OIL-IN-WATER EMULSION L'OREAL (FR) 2025-05-08 WO claimed
EP-4543408-A1 SOLUBILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME L'OREAL (FR) 2025-04-30 EP claimed
CN-119654151-A Composition for caring skin 莱雅公司 2025-03-18 CN claimed
CN-119630382-A Solubilization of thiopyridone compounds and compositions containing same 莱雅公司 2025-03-14 CN claimed
EP-4479146-A1 COSMETIC COMPOSITION The Boots Company PLC (GB) 2024-12-25 EP claimed
EP-0896522-B1 METHODS OF REGULATING SKIN APPEARANCE WITH VITAMIN B 3 COMPOUND PROCTER & GAMBLE (US) 2003-10-22 EP claimed
WO-2003082191-A2 SUBSTITUTED 2,3-DIPHENYL PYRIDINES MERCK & CO., INC. (US) 2003-10-09 WO claimed
WO-2002069916-A2 ANHYDROUS ANTIPERSPIRANT AND DEODORANT COMPOSITIONS CONTAINING A SOLID, WATER-SOLUBLE, SKIN ACTIVE AGENT THE PROCTER & GAMBLE COMPANY (US) 2002-09-12 WO claimed
US-6383476-B1 Anhydrous antiperspirant and deodorant compositions containing a solid, water-soluble, skin active agent THE PROCTER & GAMBLE COMPANY 2002-05-07 US claimed
EP-1094816-A4 BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2001-12-19 EP claimed
EP-1094816-A1 BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2001-05-02 EP claimed
WO-2000001389-A1 BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS BRISTOL-MYERS SQUIBB CO. (US) 2000-01-13 WO claimed
US-5939568-A Accelerated catalysis of olefinic epoxidations THE SCRIPPS RESEARCH INSTITUTE (US) 1999-08-17 US claimed
WO-1998033786-A9 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS 1998-12-30 WO claimed
WO-1998033786-A1 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS THE SCRIPPS RESEARCH INSTITUTE (US) 1998-08-06 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250161201-A1 COSMETIC COMPOSITION CYP19A1, SHBG, HSD17B11 THRB 3106/4885GAA 1394/4885MEN1 2548/4885
US-20250381116-A1 SOLUBILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME TBCB, CCNB3, CYP24A1 THRB 494/4885GAA 4523/4885MEN1 1459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.